Clinical trial · Interventional
Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma
NCT03212261CI-TRIAL-00054984completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3RP-Lymphoma | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 3RP-Lymphoma
- description
- -An adapted version of the 3RP (3RP-Lymphoma) for lymphoma survivors recently completing cancer treatment. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.
- interventionNames
- Behavioral: 3RP-Lymphoma
Primary outcomes (2)
- measure
- Program Feasibility: Number of Participants Who Completed at Least 75% of the Treatment Sessions
- timeFrame
- 1 month after completing the 3RP-Lymphoma program
- description
- The investigators will evaluate program feasibility by examining rates of treatment completion. Participants who complete at least 75% of the treatment sessions will be identified as treatment completers.
- measure
- Number of Participants Who Found the 3RP Program Acceptable
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 64 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18-64 * Within 2 years post-treatment completion for lymphoma * English speaking * Able and willing to provide informed consent * Cancer treatment or follow-up for lymphoma at the MGH Cancer Center Exclusion Criteria: * Unwilling or unable to participate in the study * Unable to speak or read English * Is medically, psychiatrically, or otherwise unable to participate (as determined by a physician or study PI) * Unwilling or unable to participate in group 3RP sessions delivered via the Partners Telehealth videoconferencing software * Participation in qualitative interview during Phase 1 (DF/HCC 16-396)
References
Publications (0)
Data not yet available
No reference posted for this study.